For personal use only

Quarterly Activities Report

For the period ending 30 September 2021

- **Medgate AG, the leading European provider of digital health and telehealth services successfully completed pilot trial and signed license agreement to use ResAppDx in Europe and the Philippines**
- **Australia's largest private telehealth business, Doctors on Demand, and Indonesia's largest provider of telehealth services, Alodokter, signed license agreements to integrate ResAppDx into their platforms**
- **COVID-19 clinical program reaches milestone of 100 positive COVID-19 patients recruited with data analysis to now commence**
- **510(k) premarket notification submitted to the US FDA for SleepCheckRx**

Brisbane, Australia, 28 October 2021 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to provide an activities update for the three month period ended 30 September 2021 ("Q1 FY2022").

OPERATIONAL HIGHLIGHTS

ACUTE RESPIRATORY DIAGNOSIS

Medgate AG ("Medgate") enters license agreement to use ResAppDx

Medgate completed a pilot of ResAppDx, ResApp's smartphone-based acute respiratory diagnostic test, across its telemedicine services during the first half of calendar year 2021. Following the successful completion of the pilot, Medgate signed a commercial non-exclusive license agreement to use ResAppDx on its telehealth platform across Europe and the Philippines.

ResAppDx is now live on Medgate's iOS and Android App and is available in Europe. Medgate's app allows patients to easily and quickly contact their doctor and obtain medical advice and treatment 24 hours a day, 7 days a week. If a patient has symptoms that suggest respiratory disease, Medgate's AI automatically initiates a ResAppDx diagnostic test.

Medgate has seen increasing use of ResAppDx during the quarter and importantly, continued high patient satisfaction and increasing clinician confidence. Medgate also continues to see clinical results that are consistent with ResApp's strong clinical trial data.

Alodokter to launch ResAppDx in its telehealth service in Indonesia

In August, ResApp signed a software license agreement with Indonesian-based telehealth company Alodokter. The Alodokter platform connects more than 50,000 doctors and 1,500 hospitals and clinics with millions of Indonesian patients. It also provides a wide array of

For personal use only

services around telemedicine such as offline doctor booking, insurance services, e-pharmacy and digital healthcare content.

Alodokter is currently integrating ResAppDx into its chat and telehealth services and expects to launch ResAppDx on its platform prior to 1 December 2021. ResApp secured Indonesian regulatory approval for ResAppDx in September.

Commercial agreement signed with Doctors on Demand
ResApp signed a commercial agreement with the Australian-based private telehealth provider Doctors on Demand in July. Doctors on Demand offers both direct-to-consumer (B2C) and business-to-business (B2B) offerings for patients with a wide range of telehealth services. Its customers include Flight Centre, Allianz Partners and one of the world's largest mining companies.

ResApp is working closely with Doctors on Demand to integrate its ResAppDx App Clips product into Doctors on Demand's telehealth platform, with a product launch expected by the end of this calendar year.

COVID-19 INSTANT SCREENING TEST

Collection of data in the United States and expansion to collect longitudinal data
During the quarter, ResApp continued to recruit patients in its US-based SARS-CoV2 ("COVID-19") clinical study. The COVID-Cough Study aims to collect cough sounds and polymerase chain reaction (PCR) COVID-19 test results to train an algorithm to instantly identify COVID-19 using only a smartphone.

In August, ResApp expanded the program by including the collection of longitudinal data for subjects who are COVID-19 positive. This additional data on disease progression and any medical care received will allow ResApp to develop algorithms to remotely monitor patients with COVID-19 and help healthcare providers optimise medical care.

Recruitment in ResApp's US-based COVID-19 studies is expected to be complete in mid-December.

Completed recruitment of 100 positive cases in India and expansion of recruitment
ResApp announced the expansion of its COVID-19 clinical program to India in August and began recruitment at three hospital sites in September. The combination of data from India and the US will be crucial to test the robustness of algorithms across population groups.

In October, the company announced that it had completed recruitment of 100 COVID-19 patients in India ahead of schedule. Given the fast recruitment and the value of additional data, the study was expanded to 200 positive cases and is expected to complete by the end of November 2021.

ResApp has now commenced analysis of the data collected in India and the US.

For personal use only

SLEEP APNOEA SCREENING

510(k) premarket notification submitted to the US FDA for SleepCheckRx
In October, ResApp submitted a 510(k) premarket notification to the US Food and Drug Administration (FDA) for SleepCheckRx, a prescription-only, software-as-a-medical-device (SaMD) smartphone application for at-home sleep apnoea screening. FDA clearance would unlock a substantial market opportunity for ResApp. It is estimated that 42 million American adults suffer from sleep disordered breathing (SDB) and three in ten men and almost one in five women have sleep apnoea. It is further estimated that 75% of SDB cases remain undiagnosed.

The targeted time period for review of a 510(k) application by the FDA is 90 days.

COMPANY

Advanced and Overseas R&D finding received for COVID-19 clinical studies
ResApp has received approval from AusIndustry for its application for an Advanced and Overseas Finding in respect to expenditure associated with its COVID-19 clinical studies. The company now estimates that it will receive an R&D rebate of approximately $820,000 for the financial year ended 30 June 2021.

FIRST QUARTER FINANCIAL RESULTS

Receipts from customers for the quarter totalled $7,000 (Q4 FY2021: $35,000).

Overall cash decrease was $2,151,000 (Q4 FY2021: increased by $3,386,000), with net cash used in operating activities totalling $2,104,000 (Q4 FY2021: $1,720,000). Research and development payments increased to $558,000 (Q4 FY2021: $483,000) due to costs associated with ResApp's COVID-19 clinical programs. Advertising and marketing costs decreased to $53,000 (Q4 FY2021: $94,000). Staff costs slightly increased to $982,000 (Q4 FY2021: $971,000). The company made payments of $170,000 to directors during the period ($50,000 for non-executive director fees and $120,000 for executive director fees).

ResApp retained a cash balance of $4.4m at the end of the quarter.

MANAGEMENT COMMENTARY

CEO and Managing Director Dr Tony Keating said: *"We were delighted to secure our first commercial telehealth license agreement in Europe during the quarter. Medgate is a globally recognised leader in telehealth and we were pleased to convert from a pilot agreement to a full commercial license. This agreement with Medgate, as well as recent licensing agreements with Alodokter, Indonesia's largest telehealth provider, and Doctors on Demand, Australia's largest private telehealth business, will significantly increase the use of ResAppDx, helping increase clinician confidence in our technology.*

"From a product development perspective, our team is focused on our COVID-19 clinical program. We were pleased to recently announce that we had reached our initial target for recruitment of COVID-19 positive patients in India ahead of time. We have, for the last few months, been performing

For personal use only

foundational work on algorithm candidates to prepare for the task of training and validating those candidates on COVID-19 clinical data. We now have sufficient data from India and the US to start the next stage in algorithm development. With years of experience in cough-based algorithms for acute respiratory disease diagnosis, our team is uniquely positioned to build a smartphone-based screening test for COVID-19. We are excited about the opportunity to help individuals, companies, healthcare providers, healthcare systems and governments manage the virus."

CONFERENCE CALL DETAILS

Shareholders are invited to join a conference call hosted by Managing Director and CEO, Dr Tony Keating at 11:00am Australian Eastern Daylight Time (AEDT) today. Shareholders can pre-register for the call by following the link below. Registered participants will receive a calendar notification with dial-in details and a PIN to access the call.

https://s1.c-conf.com/diamondpass/10017654-4msk65.html

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

For personal use only

Name of entity	
ResApp Health Limited	
ABN	**Quarter ended ("current quarter")**
51 094 468 318	**30 September 2021**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	7	7
1.2	Payments for		
	(a) research and development	(558)	(558)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	(53)	(53)
	(d) leased assets	-	-
	(e) staff costs	(982)	(982)
	(f) administration and corporate costs	(522)	(522)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	4	4
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(2,104)**	**(2,104)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(9)	(9)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

For personal use only

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(9)**	**(9)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Payment of lease liability	(38)	(38)
3.10	**Net cash from / (used in) financing activities**	**(38)**	**(38)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	6,587	6,587
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,104)	(2,104)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(9)	(9)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(38)	(38)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**4,436**	**4,436**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	4,436	6,587
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**4,436**	**6,587**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(170)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 above includes Directors fees and salaries (including superannuation) for Managing Director and Executive Director, Corporate Affairs.

For personal use only

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,104)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,436
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,436
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**2**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

For personal use only

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

28 October 2021

Date: .....

Tony Keating

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only